May 19, 2020 / 11:16 AM / 12 days ago

BRIEF-New Data Demonstrates Significant And Risk-Appropriate Clinical Impact Of Decisiondx-Scc Test Results On Patient Management Decisions

May 19 (Reuters) - Castle Biosciences Inc:

* NEW DATA DEMONSTRATES SIGNIFICANT AND RISK-APPROPRIATE CLINICAL IMPACT OF DECISIONDX-SCC TEST RESULTS ON PATIENT MANAGEMENT DECISIONS

* CASTLE BIOSCIENCES INC - TEST IS EXPECTED TO BE LAUNCHED COMMERCIALLY IN Q3 OF 2020 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below